Company intelligence / Profile preview
Gema Biotech S.A.
San Isidro / Olivos, Buenos Aires Province, Argentinagemabiotech.com ↗
- Ownership
- Private
- Employees
- ~375
- Development stage
- Other
01
Overview
Gema Biotech has advanced a biosimilar of follitropin alfa targeting infertility and is conducting a Phase 3 clinical trial of Enerceptan® in combination with methotrexate for rheumatoid arthritis. The status of these programs includes at least one pending approval and an ongoing or recently completed Phase 3 study, though some trial statuses are listed as "unknown."[1]
- Therapeutic areas
- Women's HealthRheumatology
- Modalities
- Recombinant proteinsBiosimilars (e.g., Follitropin alfa biosimilar)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Gema Biotech S.A..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gema Biotech S.A..